The Use of Angiotensin II for the Treatment of Post-cardiopulmonary Bypass Vasoplegia.

ABSTRACT:

Purpose

Vasoplegia is a common complication after cardiac surgery and is related to the use of cardiopulmonary bypass (CPB). Despite its association with increased morbidity and mortality, no consensus exists in terms of its treatment. In December 2017, angiotensin II (AII) was approved by the Food and Drug Administration (FDA) for use in vasodilatory shock; however, except for the ATHOS-3 trial, its use in vasoplegic patients that underwent cardiac surgery on CPB has mainly been reported in case reports. Thus, the aim of this review is to collect all the clinically relevant data and describe the pharmacologic mechanism, efficacy, and safety of this novel pharmacologic agent for the treatment of refractory vasoplegia in this population.

Methods

Two independent reviewers perf

SUBMITTER: Papazisi O 

PROVIDER: S-EPMC9270278 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature